GlassScriptPhysician profile
Kevin Seth Steinberg
NPI 1376698852
$2,424.98
in general payments reported to CMS, 2019-2025
16 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.15 · 2022: $21.81 · 2023: $1,619 · 2024: $444 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,505 · Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,505.00 |
| Food and Beverage | $867.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $1,505.00 | 2023 | |
| Boston Scientific Corporation | $447.17 | 2023-2025 | Avvigo Guidance System, Watchman Flx |
| Heartflow, INC. | $102.54 | 2025 | |
| Amgen INC. | $64.98 | 2023-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $39.87 | 2024 | Wainua |
| Abbott Laboratories | $35.58 | 2023-2024 | Cardiomems, Diamondback Peripheral |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.15 | 2019 | |
| Acarix USA INC. | $27.22 | 2024 | Cadscor System |
| Kiniksa Pharmaceuticals, LTD. | $26.14 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $25.27 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $24.23 | 2024 | Nexletol |
| Novo Nordisk INC | $23.56 | 2024 | |
| Impulse Dynamics (USA) INC. | $21.81 | 2022 | |
| Abiomed | $18.86 | 2025 | |
| Pfizer INC. | $16.20 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.40 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.